No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AFMD Affimed NV
- 4.8800
- 0.00000.00%
Close Apr 25 16:00 ET
- 4.9900
- +0.1100+2.25%
Post 18:53 ET
74.31MMarket Cap-643P/E (TTM)
4.9900High4.5600Low71.16KVolume4.8800Open4.8800Pre Close337.32KTurnover0.53%Turnover RatioLossP/E (Static)15.23MShares11.100052wk High1.20P/B65.88MFloat Cap2.235052wk Low--Dividend TTM13.50MShs Float242.0000Historical High--Div YieldTTM8.81%Amplitude2.2350Historical Low4.7400Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Affimed Announces Acceptance of AFM24 Clinical Abstract For EGFR-wildtype (EGFRwt) Non-Small Cell Lung Cancer (NSCLC) At The 2024 Annual Meeting Of The American Society Of Clinical Oncology
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Express News | Affirmed Shares Are Trading Higher After HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $5 to $10
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
Express News | Cantor Fitzgerald Reiterates Overweight on Affimed
Affimed Price Target Raised to $5.00/Share From $1.00 by Stifel
Affimed Price Target Raised to $5.00/Share From $1.00 by Stifel
Comments
$Affimed NV(AFMD.US$
NEWS
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (Nasdaq: AFMD) announces the acceptance of the AFM24 clinical abstract at the 2024 ASCO Annual Meeting. The phase 2 study on AFM24 in combination with atezolizumab in patients with EGFR wild-type non-small cell lung cancer has been accepted for poster presentation. The abstract will be available on ASCO's website on May 23, 2024.
NEWS
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (Nasdaq: AFMD) announces the acceptance of the AFM24 clinical abstract at the 2024 ASCO Annual Meeting. The phase 2 study on AFM24 in combination with atezolizumab in patients with EGFR wild-type non-small cell lung cancer has been accepted for poster presentation. The abstract will be available on ASCO's website on May 23, 2024.
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
2
$Affimed NV(AFMD.US$
Dump the Junk
Dump the Junk
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg